second-line regime

QUESTION:

RESPONSE FROM:   

Hello and thank you for your post.

In short, yes. I'd think that the regimen of tenofovir+FTC (Truvada) and lopinavir/ritonavir (Kaletra) should retain very good antiviral activity in a patient harboring virus with the resistance pattern that you've listed.

In this case, any boosted PI would retain activity (provided that there was no prior treatment failure of protease inhibitors), and tenofovir+FTC will likely be sufficiently active, even in the presence of the M184V mutation that causes 3TC/FTC resistance.

I hope this helps. Thanks for reading.

BY

Visitors submitting questions remain solely responsible for the content of their messages. Information provided by experts is general only and should not be used for diagnosing or treating a health problem or a disease, or relied upon as legal or other professional advice. This information is not a substitute for professional advice or care.